Abstract:Hepatic fibrosis is an essential pathology of multiple chronicliverdiseases. The aim of this study was to investigate the role of miR-301a-3p in hepatic fibrosis. We found that miR-301a-3p was upregulated in hepatic fibrosis patients and in culture-activated human hepatic stellate cells (HSCs). Interestingly, miR-301a-3p expression was increased in hepatic fibrosis progression mice while decreased in hepatic fibrosis recovery mice, indicating that miR-301a-3p may participate in the hepatic fibrosis pathology. Functionally, the effects of miR-301a-3p both on hepatic fibrosis progression and regression were assessed in vivo. Inhibiting miR-301a-3p amelioratedmouse liver fibrogenesis and collagen deposition and suppressed HSC activation and fibrogenic factor expression. Whereas, in hepatic fibrosis regression, upregulating miR-301a-3p impaired mouse hepatic fibrosis recovery by inducing HSC activation and triggering inflammation. Consistently, gain-of-function and loss-of-function analysis of miR-301a-3p were performed to evaluate its effects on human HSCs LX-2 cell. We found that suppressing miR-301a-3p inhibited LX-2 cell activation and proliferation, and induced LX-2 cell apoptosis, accompaniedby decreased fibrotic mediators expression. Collectively, these findings suggest miR-301a-3p drives liver fibrogenesis and HSC activation in hepatic fibrosis. Mechanistically, we demonstrated miR-301a-3p binds directly to phosphatase and tensin homolog (PTEN) by luciferase reporter analysis, pull-down, and RIP assay. Indicating that miR-301a-3p plays a critical rolein promotingliverfibrogenesis viamodulating the PTEN/platelet derived growth factor β (PDGFR-β) pathway. In conclusion, our findings demonstrate that miR-301a-3p expression is closely correlated with hepatic fibrosis pathology, and that enhancing miR-301a-3p maintains the HSC profibrogenic phenotype, triggers inflammatoryresponses, promotes fibrogenic factor production, and further exacerbates liver fibrogenesis. These findings suggest that miR-301a-3p may serve as a promising diagnostic and prognosis biomarker for hepatic fibrosis treatment.

MiR-338* Suppresses Fibrotic Pathogenesis in Pulmonary Fibrosis Through Targeting LPA1.

MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition.

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MiR-340-5p mitigates the proliferation and activation of fibroblast in lung fibrosis by targeting TGF-/p38/ATF1 signaling pathway

Mir-301A Suppression Within Fibroblasts Limits the Progression of Fibrosis Through the TSC1/mTOR Pathway

Mir-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice

Regulation of idiopathic pulmonary fibrosis: a cross-talk between TGF- β signaling and MicroRNAs

LncRNA Hoxaas3 Promotes Lung Fibroblast Activation and Fibrosis by Targeting Mir-450B-5p to Regulate Runx1.

Toll Like Receptor 4 Activation Upregulates Mir-181B Attenuating Pulmonary Fibrosis Via Targeting TGFBR1

miR-627/HMGB1/NF-κB regulatory loop modulates TGF-β1-induced pulmonary fibrosis.

Tectorigenin Inhibits the in Vitro Proliferation and Enhances Mir-338* Expression of Pulmonary Fibroblasts in Rats with Idiopathic Pulmonary Fibrosis.

MicroRNA‐448 overexpression inhibits fibroblast proliferation and collagen synthesis and promotes cell apoptosis via targeting ABCC3 through the JNK signaling pathway

MicroRNA-708-3p as a potential therapeutic target via the ADAM17-GATA/STAT3 axis in idiopathic pulmonary fibrosis

MiR-125b-5p alleviates pulmonary fibrosis by inhibiting TGFβ1-mediated epithelial-mesenchymal transition via targeting BAK1

LncRNA PFAR Contributes to Fibrogenesis in Lung Fibroblasts Through Competitively Binding to Mir-15A.

MiRNA, a New Treatment Strategy for Pulmonary Fibrosis

LAPTM4B Alleviates Pulmonary Fibrosis by Enhancing NEDD4L-Mediated TGF-β Signaling Suppression

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

MicroRNA-27a-3p is a Negative Regulator of Lung Fibrosis by Targeting Myofibroblast Differentiation

Mmu-Microrna-92a-3p Attenuates Pulmonary Fibrosis by Modulating Cpeb4-mediated Smad2/3 Signaling Pathway

Mir-200B/c Attenuates Lipopolysaccharide-Induced Early Pulmonary Fibrosis by Targeting ZEB1/2 Via P38 MAPK and TGF-β/smad3 Signaling Pathways